Skip to content

Long-term Evaluation of the Efficacy and Safety of Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Prospective, Multicenter, 60 Months, Single-arm Cohort Trial for Evaluation of the Efficacy and Safety of Transvaginal Sacrospinous Ligament Fixation With Splentis for the Treatment of Primary Apical Pelvic Organ Prolapse

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05042453
Acronym
SAXO
Enrollment
140
Registered
2021-09-13
Start date
2022-12-19
Completion date
2030-07-31
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Organ Prolapse

Keywords

Apical Pelvic Organ Prolapse, Transvaginal repair, Mesh augmented repair, Sacrouterine ligament fixation

Brief summary

This prospective, multi center cohort trial aims to evaluate the efficacy and safety of hysteropexy using Splentis via the vaginal route in primary uterine prolapse

Detailed description

Women who undergo hysteropexy with Splentis via the vaginal route for primary uterine prolapse will be evaluated regarding efficacy and safety in a long term follow-up of 60 months. The primary endpoint is composed of anatomical, subjective and re-treatment components, whereas several secondary endpoints focusing on functional outcome including overactive bladder symptoms, urinary incontinence, quality of life and sexual life will be considered. Furthermore, a detailed report about adverse events will be included.

Interventions

DEVICESplentis® POP Tissue Anchoring System

Anterior cervicopexy with bilateral sacrospinous ligament fixation using Splentis

Sponsors

Promedon
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* non-fertile women * primary symptomatic uterine descent POP-Q≥2 * Scheduled apical POP repair with Splentis * Willing and able to participate at study visits and to sign informed consent

Exclusion criteria

* Fertile women * Recurrent apical prolapse * Women with post hysterectomy vaginal vault prolapse * Patients with active or latent infection of the vagina, cervix or uterus * Patients with previous or current vaginal, cervical or uterine cancer * Previous, current or planned pelvic radiation therapy * Known allergy to polypropylene.

Design outcomes

Primary

MeasureTime frameDescription
Cure of apical pelvic organ prolapse12 monthsCure of apical pelvic organ prolapse is defined according the current recommendations by Barber et al. and ICS/IUGA recommendations. Therefore, a combined endpoint using anatomical, subjective and necessity retreatment criteria are utilized. Primary endpoint is the number of patients achieving all criteria of the composite endpoint: 1. leading edge of the apical vaginal wall at or above the hymen (C≤ 0) 2. absence of a vaginal bulge symptom 3. no need for retreatment of the apical prolapse by either pessary use or surgical intervention

Secondary

MeasureTime frameDescription
Quality of lifeBaseline, 6 weeks and 12, 24, 36, 60 monthsChange of quality of life using the EQ-5L-5D in comparison between baseline and follow-up. It consists of a 5-item descriptive system as well as a visual analogue scale ranging from 0 to 100. It is conceptualized to assess deviation from health and hereby provide health related quality of life problems.
Urinary incontinenceBaseline, 6 weeks and 12, 24, 36, 60 monthsChange of urinary incontinence using the International Consultation on Incontinence Questionnaire- Urinary Incontinence Short From in comparison between baseline and follow-up The ICIQ-UI-SF includes four items with a sum score ranging between 0 and 21 points. The higher the score the higher the impact of symptoms.
Overactive BladderBaseline, 6 weeks and 12, 24, 36, 60 monthsChange of urinary incontinence using the International Consultation on Incontinence Questionnaire- Overactive bladder in comparison between baseline and follow-up The score of the ICIQ-OAB ranges from 0 to 16 points. The higher the sum score the higher the impact of symptoms.
Sexual lifeBaseline, 6 weeks and 12, 24, 36, 60 monthsChange of sexual life using the Pelvic Organ Prolapse Incontinence Sexual Questionnaire- IUGA revised in comparison between baseline and follow-up. The result will be transformed into a scale between 0 - 100. The higher the score, the higher the impact of prolapse symptoms and the higher the impact on sexual life.
Health-related quality of lifeBaseline, 6 weeks 12, 24, 36, 60 monthsChange of Quality of life and prolapse symptoms using the Prolapse-Quality of Life-Questionnaire in comparison between baseline and follow-up. The questionnaire is divided in nine domains which are analyzed separately. The results will be transformed into a scale between 0 - 100 according the questionnaires description. The higher the score, the higher the impact of prolapse symptoms and the lower the quality of life.
Patient global impression of improvement6 weeks and 12, 24, 36, 60 monthsNumber of Patients with improvement of prolapse symptoms according the validated question Patient Global Impression of improvement The PGI-I is a seven Likert scale from very much better to no change and very much worse.
Cure according composite endpoint6 weeks and 24, 36, 60 monthsNumber of patients completing each component of the composite endpoint
Adverse EventsIntraoperatively, 24-48hours postoperatively, 6 weeks postoperatively and 12, 24, 36, 60 months, unscheduled visitsNumber and severity of Adverse Events according guideline of AE reporting, Clavien Dindo and Terminology of IUGA/ICS
Exposure and extrusion free survival6 weeks and 12, 24, 36, 60 monthsEstimated exposure and extrusion free survival according Kaplan-Meier.
Pain according Visual analogue scale of painBaseline, 24-48 hours postoperatively, 6 weeks and 12, 24, 36, 60 monthsChange of pain using the visual analogue scale of pain in comparison between baseline and follow-up The Wong-Baker Faces Pain Scale is a visual analogue scale to assess subject pain.The answers will be transformed in a scale from 0 to 10 whereas 0 implicate no pain and 10 worst pain.

Countries

Germany

Contacts

Primary ContactPhilipp Schelhorn
trials.de@promedon.com00498031900400
Backup ContactLorena López, Ph.D, Bioeng
lorena.lopez@promedon.com005493514596072

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026